Literature DB >> 36103008

A method to obtain purified free light chain monomers and dimers from urine samples of patients with multiple myeloma.

Laura Caponi1, Alice Botti2, Nadia Romiti2, Aldo Paolicchi2, Maria Franzini2.   

Abstract

Antibody light chains are synthesized in excess by plasma cells, and this excess can be secreted into biological fluids as dimers or monomers in various proportions. Structural differences between monomers or dimers of free light chains (FLC) can affect their biological functions and possibly their pathogenicity. They also may exhibit differential immune reactivity, perhaps explaining discrepant quantifications when measured by different immunoreagents. Having purified FLC monomers and dimers available can be useful for studying their properties. Here we propose a simple preparatory procedure to purify FLC monomers and dimers from urine samples of patients with plasma cell disorders. Two representative urine samples containing lambda or kappa FLC were loaded into a nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gel strips containing separate monomers and dimers were excised, electroeluted, and the FLC recovered. The FLC were recovered from SDS-PAGE gel in sufficient amounts to be quantified by UV and two automated nephelometric assays immunochemical. The procedure was found to be simple, reproducible, and with a high yield, thus offering the opportunity to compare different assays. Not all urine samples are suitable for this procedure, but this approach allows for the purification of FLC monomers and dimers from many selected urine samples which maintain their oligomeric organization.
© 2022. The Author(s).

Entities:  

Keywords:  Dimers; Free light chains; Monomers; Multiple myeloma

Year:  2022        PMID: 36103008     DOI: 10.1007/s12026-022-09314-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  23 in total

Review 1.  The biology of immunoglobulin free light chains and kidney injury.

Authors:  Kolitha Basnayake; Stephanie J Stringer; Colin A Hutchison; Paul Cockwell
Journal:  Kidney Int       Date:  2011-04-13       Impact factor: 10.612

2.  Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis.

Authors:  Batia Kaplan; Sizilia Golderman; Gilad Yahalom; Regina Yeskaraev; Tamar Ziv; Boris M Aizenbud; Ben-Ami Sela; Avi Livneh
Journal:  J Immunol Methods       Date:  2013-01-31       Impact factor: 2.303

3.  Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.

Authors:  Batia Kaplan; Sizilia Golderman; Boris Aizenbud; Konstantin Esev; Olga Kukuy; Merav Leiba; Avi Livneh; Ilan Ben-Zvi
Journal:  Am J Hematol       Date:  2014-06-27       Impact factor: 10.047

Review 4.  Free light chains: Eclectic multipurpose biomarker.

Authors:  Umberto Basile; Francesca Gulli; Laura Gragnani; Cecilia Napodano; Krizia Pocino; Gian Ludovico Rapaccini; Michele Mussap; Anna Linda Zignego
Journal:  J Immunol Methods       Date:  2017-09-18       Impact factor: 2.303

5.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

6.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

Review 7.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

8.  Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition.

Authors:  E A Myatt; F A Westholm; D T Weiss; A Solomon; M Schiffer; F J Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

Review 9.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

Review 10.  The Proximal Tubule Toxicity of Immunoglobulin Light Chains.

Authors:  Christophe Sirac; Vecihi Batuman; Paul W Sanders
Journal:  Kidney Int Rep       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.